A mid-size, top 5 European pharmaceutical company engaged PRA in a global Phase III study in 20 countries on patients with advanced breast cancer previously treated with or resistant to airmaximus an anthracycline and who are taxane resistant. By identifying optimal sites in in Russia, Ukraine, Belarus, and Estonia, PRA recruited 318 patients at 25 sites, compared to 450+ patients at 150 sites in Rest of World (ROW).
The Center for Immuno-oncology, Cellular, and Gene Therapy
We provide end-to-end support for your complex, fast-paced immunotherapy studies.
Recruiting Solid Tumor Patients in a Complex ADME Trial
PRA's PPS facility in Budapest (PPS-Hungary) was contracted to run an open-label, non-randomized, Phase I study to characterize the mass balance and…
Virtual Technology Strives to Make Better Research and Treatments for All
The use of virtual reality (VR) technology, wearable technology, and virtual clinical trials can provide researchers with a more convenient way to…